Hemophilia

Emicizumab Prophylaxis Cuts Bleeding in Hemophilia A

Emicizumab Prophylaxis Cuts Bleeding in Hemophilia A

Lower bleeding rate with administration once weekly, every 2 weeks vs no prophylaxis.

FDA approves new hemophilia A drug with factor VIII inhibitors

FDA approves new hemophilia A drug with factor VIII inhibitors

New FDA-approved prophylactic treatment decreases bleeding episodes hemophilia A patients with factor VIII inhibitors.

Sign Up for Free e-newsletters